Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
4.41M
-
Shares change
-
+509K
-
Total reported value, excl. options
-
$33.3M
-
Value change
-
+$3.97M
-
Number of buys
-
10
-
Number of sells
-
-12
-
Price
-
$7.55
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2017
33 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q3 2017.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.41M shares
of 28.5M outstanding shares and own 15.48% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (3.6M shares), BlackRock Inc. (190K shares), Artal Group S.A. (150K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (145K shares), VANGUARD GROUP INC (134K shares), NORTHERN TRUST CORP (43.9K shares), Destination Wealth Management (29.7K shares), GEODE CAPITAL MANAGEMENT, LLC (22K shares), Family Management Corp (20.6K shares), and Bank of New York Mellon Corp (17.1K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.